
FDA Approves New Treatment for Advanced Endometrial Cancer
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca UK Limited) for use with carboplatin plus paclitaxel followed by single-agent durvalumab. This approval targets …
FDA Approves New Treatment for Advanced Endometrial Cancer Read More